AbCellera Biologics
ABCL
12.83
-0.32
-2.43%
AbCellera Biologics
US · ABCL
#2215 by market cap
Listed 2020
12.83
-0.32
-2.43%
Live - 5344 symbols - heartbeat 406s ago
· 2026-10-08 07:40
Pre-market
12.64
-1.46%
After-hours
12.85
+0.16%
Overnight
12.81
-0.16%
- Market cap
- 4.16B
- P/E (TTM)i
- -23.76
- P/Bi
- 4.64
- EPSi
- -0.49
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on ABCL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.51, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +160.56% YoY
Margins
- Operating margin
- -270.49%
- Net margin
- -194.88%
Key ratios & quality
- Altman Z-Scorei
- 6.51
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.83M | 11.61M | 233.16M | 375.20M | 485.42M | 38.03M | 28.83M | 75.13M |
| Gross profit | 8.83M | 11.61M | 206.01M | 329.69M | 418.99M | -- | -- | -- |
| Selling & admin expenses | 2.86M | 4.01M | 15.75M | 48.76M | 66.76M | 75.18M | 85.49M | 83.23M |
| Research & development | 5.80M | 10.11M | 29.39M | 62.06M | 107.88M | 175.66M | 167.26M | 186.83M |
| Operating profit | 841.00K | -2.34M | 164.35M | 221.90M | 227.07M | -223.05M | -301.15M | -203.21M |
| Pretax profit | 309.00K | -2.21M | 157.83M | 219.15M | 239.10M | -174.03M | -200.40M | -177.60M |
| Tax | 0 | 0 | 38.92M | 65.69M | 80.58M | -27.63M | -37.54M | -31.18M |
| Net profit | 309.00K | -2.21M | 118.92M | 153.46M | 158.52M | -146.40M | -162.86M | -146.41M |
| Basic EPS | 0 | 0 | 1 | 1 | 1 | -1 | -1 | 0 |
| Diluted EPS | 0.00 | -0.01 | 0.45 | 0.48 | 0.50 | -0.51 | -0.55 | -0.49 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.24M | 17.08M | 8.96M | 44.85M | 8.32M | 4.05M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 19.07M | 21.99M | 24.96M | 17.22M | 12.33M | 13.85M |
| Research & development | 42.50M | 39.21M | 55.03M | 50.09M | 46.66M | 45.99M |
| Operating profit | -58.51M | -45.89M | -73.55M | -25.27M | -53.18M | -58.92M |
| Pretax profit | -52.98M | -36.34M | -68.77M | -19.50M | -49.54M | -58.97M |
| Tax | -7.36M | -1.62M | -11.65M | -10.55M | -6.37M | -3.54M |
| Net profit | -45.62M | -34.73M | -57.12M | -8.95M | -43.17M | -55.43M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.15 | -0.12 | -0.19 | -0.03 | -0.14 | -0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 15.16M | 12.64M | 813.33M | 929.80M | 1.03B | 871.99M | 751.37M | 728.23M |
| Cash & ST investments | 10.44M | 7.55M | 594.12M | 722.98M | 886.49M | 760.59M | 625.61M | 533.83M |
| Inventory | -- | 163.00K | 1.41M | 1.67M | 1.53M | -- | 0 | 6.34M |
| Total assets | 21.49M | 23.49M | 1.01B | 1.32B | 1.54B | 1.49B | 1.36B | 1.36B |
| Total current liabilities | 6.43M | 7.90M | 103.49M | 120.68M | 118.32M | 119.01M | 76.61M | 64.31M |
| Short-term debt | 2.53M | 2.89M | 675.00K | 3.65M | 5.58M | 6.16M | 4.62M | 5.82M |
| Long-term debt | 911.22K | 1.36M | -- | -- | -- | -- | -- | -- |
| Total liabilities | 9,882,972.00 | 13,236,000.00 | 175,028,000.00 | 292,836,000.00 | 307,630,000.00 | 335,776,000.00 | 304,469,000.00 | 390,046,000.00 |
| Total equity | 11.61M | 10.25M | 830.51M | 1.03B | 1.23B | 1.15B | 1.06B | 966.90M |
| Retained earnings | -2.50M | -4.72M | 114.20M | 267.67M | 426.19M | 279.79M | 116.93M | -29.48M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 764.98M | 742.15M | 695.14M | 728.23M | 664.60M | 679.23M |
| Cash & ST investments | 605.27M | 553.08M | 495.67M | 533.83M | 504.73M | 540.10M |
| Inventory | -- | -- | -- | 6.34M | 7.86M | 7.58M |
| Total assets | 1.34B | 1.40B | 1.36B | 1.36B | 1.31B | 1.31B |
| Total current liabilities | 75.40M | 67.02M | 68.80M | 64.31M | 47.29M | 53.19M |
| Short-term debt | 4.64M | 4.90M | 5.17M | 5.82M | 5.87M | 5.67M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 321,226,000.00 | 394,985,000.00 | 391,954,000.00 | 390,046,000.00 | 369,029,000.00 | 411,555,000.00 |
| Total equity | 1.02B | 1.01B | 964.04M | 966.90M | 938.08M | 896.02M |
| Retained earnings | 71.31M | 36.58M | -20.54M | -29.48M | -72.65M | -128.07M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.57M | 2.69M | 22.69M | 244.58M | 277.36M | -43.88M | -108.56M | -131.30M |
| Depreciation & amortization | 918.00K | 1.85M | 5.27M | 17.25M | 33.10M | 30.89M | 97.00M | 28.82M |
| Free cash flow | -1.74M | -1.30M | 8.02M | 186.13M | 204.70M | -120.82M | -186.95M | -174.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.61M | 0 | 522.84M | -- | -- | -- | -- | -- |
| Ending cash balance | 10.44M | 7.55M | 594.12M | 501.14M | 414.65M | 160.61M | 183.62M | 155.25M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -11.55M | -32.40M | -52.59M | -34.74M | -33.52M | 25.92M |
| Depreciation & amortization | 6.61M | 7.06M | 7.24M | 7.92M | 8.66M | 8.78M |
| Free cash flow | -22.19M | -45.77M | -61.52M | -44.59M | -37.35M | 23.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 186.56M | 119.73M | 110.45M | 155.25M | 103.80M | 147.03M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.21 | -65.42 | 20.43 | 16.53 | 14.03 | -12.27 | -14.75 | -14.47 |
| ROA %i | 1.36 | -9.83 | 16.54 | 13.21 | 11.09 | -9.67 | -11.43 | -10.78 |
| ROIC %i | 6.16 | -25.23 | 21.20 | 16.27 | 12.64 | -14.30 | -16.51 | -15.22 |
| 5-year avg ROE %i | -- | -- | -- | -- | -1.45 | -5.34 | 4.79 | -2.19 |
| EBIT margin %i | 5.90 | -17.24 | 70.49 | 59.80 | 50.09 | -586.59 | -1,044.45 | -270.49 |
| FCF / sales %i | -- | -- | 3.44 | 49.61 | 42.17 | -- | -- | -- |
| Current ratioi | 2.36 | 1.60 | 7.86 | 7.70 | 8.67 | 7.33 | 9.81 | 11.32 |
| Quick ratioi | 2.27 | 1.51 | 7.81 | 7.44 | 8.37 | 6.93 | 9.37 | 10.69 |
| Debt / assetsi | 16.02 | 29.34 | 0.44 | 3.04 | 5.34 | 5.20 | 4.80 | 10.55 |
| LT debt / equityi | 22.49 | 148.00 | 0.45 | 3.55 | 6.22 | 6.18 | 5.75 | 14.21 |
| Interest coveragei | 2.46 | -9.57 | 25.24 | 42.94 | 60.11 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 248.94 | 247.06 | -45.36 | -57.49 | -46.31 |
| Net income CAGR (3Y) %i | -- | -- | -- | 691.92 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -15.59 | -15.64 | -16.81 | -14.47 | -14.68 | -17.30 |
| ROA %i | -11.96 | -11.77 | -12.49 | -10.78 | -10.86 | -12.15 |
| ROIC %i | -17.14 | -16.63 | -17.53 | -15.22 | -15.29 | -16.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,332.67 | -802.36 | -699.67 | -270.49 | -249.83 | -318.75 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.15 | 11.07 | 10.10 | 11.32 | 14.05 | 12.77 |
| Quick ratioi | 9.71 | 10.54 | 9.52 | 10.69 | 13.12 | 11.95 |
| Debt / assetsi | 5.05 | 10.13 | 10.49 | 10.55 | 10.72 | 10.37 |
| LT debt / equityi | 6.18 | 13.62 | 14.22 | 14.21 | 14.32 | 14.50 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery and development of antibody drugs100.00%
Region
Canada85.22%
United States14.78%
Quote time 2026-10-08 07:40:12 · For reference only, not investment advice and not tailored to your situation.